Emily Beth Devine
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emily Beth Devine has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Nathan M. Lawless
Strategic Health Services, The Everett Clinic, Everett, WA
3 shared publicationsSean D. Sullivan
Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA
3 shared publicationsDavid K. Blough
Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA
2 shared publicationsJennifer L. Wilson-Norton
2 shared publicationsRyan N. Hansen
Pharmaceutical Outcomes Research & Policy Program, School of Pharmacy, University of Washington, Seattle, WA
2 shared publications- William Hollingworth
Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK
2 shared publications
Latest Publications
- 5 March 2016
- Published by Springer Nature
- p. 217-239
Sources of Data for Comparative Effectiveness Research
- 5 March 2016
- Published by Springer Nature
- p. 217-239
Sources of Data for Comparative Effectiveness Research
- 23 July 2015
- Published by Springer Nature
- p. 1-23
Sources of Data for Comparative Effectiveness Research
- 23 July 2015
- Published by Springer Nature
- p. 1-23
Sources of Data for Comparative Effectiveness Research
- 1 January 2012
- Vol. 18 (1) , 47-62
Systematic review of comparative effectiveness data for oncology orphan drugs.
To systematically assess clinical and economic evidence for oncology orphan drugs marketed in the United States and to highlight the challenges and opportunities for evidence development within this pharmaceutical category. Systematic review. We conducted systematic literature searches of the Medline and Embase databases for clinical and cost-effectiveness studies published before June 2010 for all oncology orphan drugs marketed in the United States. We used the Grading of Recommendations Assessment, Development and Evaluation method and the Quality of Health Economic Studies criteria to assess the quality of the selected studies. We identified 60 randomized controlled trials and 21 cost-effectiveness analyses to support 47 oncology orphan drugs. A total of 21 drugs had moderate or high-quality bodies of clinical evidence, 11 had low-quality or very low quality clinical evidence, and 15 drugs could not be evaluated because we were unable to identify clinical evidence that met our inclusion criteria. The Spearman rank correlation coefficient for the level of evidence for oncology orphan drugs and disease prevalence was 0.3 (95% confidence interval, 0.0-0.5). The cost-effectiveness analyses received quality scores between 72 and 100 (range 0-100), with a mean score of 85. The results of our study show that oncology orphan drugs marketed in the United States have varying levels and quality of clinical evidence and a paucity of evidence regarding economic value. Innovative analytic and policy approaches are needed to develop and implement a decision-making framework for this pharmaceutical category that is consistent with evidence-based medicine and comparative effectiveness research.
- 1 January 2012
- Vol. 18 (1) , 47-62
Systematic review of comparative effectiveness data for oncology orphan drugs.
To systematically assess clinical and economic evidence for oncology orphan drugs marketed in the United States and to highlight the challenges and opportunities for evidence development within this pharmaceutical category. Systematic review. We conducted systematic literature searches of the Medline and Embase databases for clinical and cost-effectiveness studies published before June 2010 for all oncology orphan drugs marketed in the United States. We used the Grading of Recommendations Assessment, Development and Evaluation method and the Quality of Health Economic Studies criteria to assess the quality of the selected studies. We identified 60 randomized controlled trials and 21 cost-effectiveness analyses to support 47 oncology orphan drugs. A total of 21 drugs had moderate or high-quality bodies of clinical evidence, 11 had low-quality or very low quality clinical evidence, and 15 drugs could not be evaluated because we were unable to identify clinical evidence that met our inclusion criteria. The Spearman rank correlation coefficient for the level of evidence for oncology orphan drugs and disease prevalence was 0.3 (95% confidence interval, 0.0-0.5). The cost-effectiveness analyses received quality scores between 72 and 100 (range 0-100), with a mean score of 85. The results of our study show that oncology orphan drugs marketed in the United States have varying levels and quality of clinical evidence and a paucity of evidence regarding economic value. Innovative analytic and policy approaches are needed to develop and implement a decision-making framework for this pharmaceutical category that is consistent with evidence-based medicine and comparative effectiveness research.
- 8 January 2010
- Published by Wiley in Health Services Research
- Vol. 45 (1) , 152-171
Electronic Prescribing at the Point of Care: A Time–Motion Study in the Primary Care Setting
Objective. To evaluate the impact of an ambulatory computerized provider order entry (CPOE ) system on the time efficiency of prescribers. Two primary aims were to compare prescribing time between (1) handwritten and electronic (e‐) prescriptions and (2) e‐prescriptions using differing hardware configurations.Data Sources/Study Setting. Primary data on prescribers/staff were collected (2005–2007) at three primary care clinics in a community based, multispecialty health system.Study Design. This was a quasi‐experimental, direct observation, time–motion study conducted in two phases. In phase 1 (n=69 subjects), each site used a unique combination of CPOE software/hardware (paper‐based, desktops in prescriber offices or hallway workstations, or laptops). In phase 2 (n=77), all sites used CPOE software on desktops in examination rooms (at point of care).Data Collection Methods. Data were collected using TimerPro software on a Palm device.Principal Findings. Average time to e‐prescribe using CPOE in the examination room was 69 seconds/prescription‐event (new/renewed combined)—25 seconds longer than to handwrite (99.5 percent confidence interval [CI] 12.38), and 24 seconds longer than to e‐prescribe at offices/workstations (99.5 percent CI 8.39). Each calculates to 20 seconds longer per patient.Conclusions. E‐prescribing takes longer than handwriting. E‐prescribing at the point of care takes longer than e‐prescribing in offices/workstations. Improvements in safety and quality may be worth the investment of time.
- 8 January 2010
- Published by Wiley in Health Services Research
- Vol. 45 (1) , 152-171
Electronic Prescribing at the Point of Care: A Time–Motion Study in the Primary Care Setting
Objective. To evaluate the impact of an ambulatory computerized provider order entry (CPOE ) system on the time efficiency of prescribers. Two primary aims were to compare prescribing time between (1) handwritten and electronic (e‐) prescriptions and (2) e‐prescriptions using differing hardware configurations.Data Sources/Study Setting. Primary data on prescribers/staff were collected (2005–2007) at three primary care clinics in a community based, multispecialty health system.Study Design. This was a quasi‐experimental, direct observation, time–motion study conducted in two phases. In phase 1 (n=69 subjects), each site used a unique combination of CPOE software/hardware (paper‐based, desktops in prescriber offices or hallway workstations, or laptops). In phase 2 (n=77), all sites used CPOE software on desktops in examination rooms (at point of care).Data Collection Methods. Data were collected using TimerPro software on a Palm device.Principal Findings. Average time to e‐prescribe using CPOE in the examination room was 69 seconds/prescription‐event (new/renewed combined)—25 seconds longer than to handwrite (99.5 percent confidence interval [CI] 12.38), and 24 seconds longer than to e‐prescribe at offices/workstations (99.5 percent CI 8.39). Each calculates to 20 seconds longer per patient.Conclusions. E‐prescribing takes longer than handwriting. E‐prescribing at the point of care takes longer than e‐prescribing in offices/workstations. Improvements in safety and quality may be worth the investment of time.
- 1 January 2010
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 17 (1) , 78-84
The impact of computerized provider order entry on medication errors in a multispecialty group practice
Computerized provider order entry (CPOE) has been shown to improve patient safety by reducing medication errors and subsequent adverse drug events (ADEs). Studies demonstrating these benefits have been conducted primarily in the inpatient setting, with fewer in the ambulatory setting. The objective was to evaluate the effect of a basic, ambulatory CPOE system on medication errors and associated ADEs. This quasiexperimental, pretest-post-test study was conducted in a community-based, multispecialty health system not affiliated with an academic medical center. The intervention was a basic CPOE system with limited clinical decision support capabilities. Comparison of prescriptions written before (n=5016 handwritten) to after (n=5153 electronically prescribed) implementation of the CPOE system. The primary outcome was the occurrence of error(s); secondary outcomes were types and severity of errors. Frequency of errors declined from 18.2% to 8.2%-a reduction in adjusted odds of 70% (OR: 0.30; 95% CI 0.23 to 0.40). The largest reductions were seen in adjusted odds of errors of illegibility (97%), use of inappropriate abbreviations (94%) and missing information (85%). There was a 57% reduction in adjusted odds of errors that did not cause harm (potential ADEs) (OR 0.43; 95% CI 0.38 to 0.49). The reduction in the number of errors that caused harm (preventable ADEs) was not statistically significant, perhaps due to few errors in this category. A basic CPOE system in a community setting was associated with a significant reduction in medication errors of most types and severity levels.
- 1 January 2010
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 17 (1) , 78-84
The impact of computerized provider order entry on medication errors in a multispecialty group practice
Computerized provider order entry (CPOE) has been shown to improve patient safety by reducing medication errors and subsequent adverse drug events (ADEs). Studies demonstrating these benefits have been conducted primarily in the inpatient setting, with fewer in the ambulatory setting. The objective was to evaluate the effect of a basic, ambulatory CPOE system on medication errors and associated ADEs. This quasiexperimental, pretest-post-test study was conducted in a community-based, multispecialty health system not affiliated with an academic medical center. The intervention was a basic CPOE system with limited clinical decision support capabilities. Comparison of prescriptions written before (n=5016 handwritten) to after (n=5153 electronically prescribed) implementation of the CPOE system. The primary outcome was the occurrence of error(s); secondary outcomes were types and severity of errors. Frequency of errors declined from 18.2% to 8.2%-a reduction in adjusted odds of 70% (OR: 0.30; 95% CI 0.23 to 0.40). The largest reductions were seen in adjusted odds of errors of illegibility (97%), use of inappropriate abbreviations (94%) and missing information (85%). There was a 57% reduction in adjusted odds of errors that did not cause harm (potential ADEs) (OR 0.43; 95% CI 0.38 to 0.49). The reduction in the number of errors that caused harm (preventable ADEs) was not statistically significant, perhaps due to few errors in this category. A basic CPOE system in a community setting was associated with a significant reduction in medication errors of most types and severity levels.
- 15 March 2009
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (6) , 580-587
The art of obtaining grants
Purpose. The grantsmanship process is described from the perspective of the investigator.
- 15 March 2009
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 66 (6) , 580-587
The art of obtaining grants
Purpose. The grantsmanship process is described from the perspective of the investigator.
- 1 March 2009
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 49 (2) , 181-191
Strategies to optimize medication use in the physician group practice: The role of the clinical pharmacist
- 1 March 2009
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 49 (2) , 181-191
Strategies to optimize medication use in the physician group practice: The role of the clinical pharmacist
- 9 May 2008
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 27 (4) , 379-384
Adherence to guidelines for the management of excessive warfarin anticoagulation
Objectives The American College of Chest Physicians (ACCP) provides guidelines for the management of excessive anticoagulation in patients receiving warfarin. This multi-site prospective cohort study evaluated patient-level practice patterns and adherence to ACCP guidelines. Methods Patients presenting with an INR ≥ 4.5 between January 3 and April 29, 2005 were observed and therapeutic management documented. Adherence was assessed retrospectively. Results Four hundred and seventeen patients from 22 centers were observed. The mean, initial INR was 7.7. At enrollment, 85% of the patients had an INR < 9 or were not bleeding; 15% were seriously bleeding. Treatment for 170 patients (41%) did not adhere to guidelines. Among those, 15% were undertreated, 48% overtreated. Lack of adherence was attributed primarily to excessive doses (mean initial dose = 6.9 mg) and inappropriate routes of administration (subcutaneous or intramuscular) of vitamin K1. Conclusion Adherence to the ACCP guidelines is low. Inappropriate use of vitamin K1 is the primary reason.
- 9 May 2008
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 27 (4) , 379-384
Adherence to guidelines for the management of excessive warfarin anticoagulation
Objectives The American College of Chest Physicians (ACCP) provides guidelines for the management of excessive anticoagulation in patients receiving warfarin. This multi-site prospective cohort study evaluated patient-level practice patterns and adherence to ACCP guidelines. Methods Patients presenting with an INR ≥ 4.5 between January 3 and April 29, 2005 were observed and therapeutic management documented. Adherence was assessed retrospectively. Results Four hundred and seventeen patients from 22 centers were observed. The mean, initial INR was 7.7. At enrollment, 85% of the patients had an INR < 9 or were not bleeding; 15% were seriously bleeding. Treatment for 170 patients (41%) did not adhere to guidelines. Among those, 15% were undertreated, 48% overtreated. Lack of adherence was attributed primarily to excessive doses (mean initial dose = 6.9 mg) and inappropriate routes of administration (subcutaneous or intramuscular) of vitamin K1. Conclusion Adherence to the ACCP guidelines is low. Inappropriate use of vitamin K1 is the primary reason.
- 15 May 2007
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (10) , 1062-1070
Characterization of prescribing errors in an internal medicine clinic
Purpose. A pilot study was conducted to characterize the epidemiology of prescribing errors, comparing those that occurred pre- to postimplementation of an electronic prescribing system; this article describes the results of the study during the preimplementation phase, when a handwritten prescription process was still in place. Summary. A retrospective review of 1411 prescriptions that were handwritten during a five-month time frame was used to identify and characterize medication errors and potential medication errors. The review was conducted in an internal medicine clinic in a large health system that was preparing to implement an electronic prescribing system. The first phase was the implementation of a basic system—one that facilitated the writing of a more complete and legible prescription. The second phase consisted of adding more sophisticated clinical decision support (CDS) capabilities. Three data sources were reviewed: the handwritten prescription, the electronic health record and the prescription as it had been entered into the pharmacy computer system. Almost 28% of the prescriptions evaluated contained one or more errors or potential errors. Over 90% of the errors were potential errors. Only 0.2% of the errors caused patient harm. Non-clinical errors (illegibility, missing information, wrong dose) may be affected by a basic electronic prescribing system, and clinical errors (drug–disease interaction, contraindication of a drug) may be affected only when more sophisticated levels of CDS programming are added. Conclusion. Potential prescribing errors occurred frequently but few reached the patient or caused harm. The most severe errors were those that may be reduced by the implementation of an electronic prescribing system with CDS capabilities.
- 15 May 2007
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 64 (10) , 1062-1070
Characterization of prescribing errors in an internal medicine clinic
Purpose. A pilot study was conducted to characterize the epidemiology of prescribing errors, comparing those that occurred pre- to postimplementation of an electronic prescribing system; this article describes the results of the study during the preimplementation phase, when a handwritten prescription process was still in place. Summary. A retrospective review of 1411 prescriptions that were handwritten during a five-month time frame was used to identify and characterize medication errors and potential medication errors. The review was conducted in an internal medicine clinic in a large health system that was preparing to implement an electronic prescribing system. The first phase was the implementation of a basic system—one that facilitated the writing of a more complete and legible prescription. The second phase consisted of adding more sophisticated clinical decision support (CDS) capabilities. Three data sources were reviewed: the handwritten prescription, the electronic health record and the prescription as it had been entered into the pharmacy computer system. Almost 28% of the prescriptions evaluated contained one or more errors or potential errors. Over 90% of the errors were potential errors. Only 0.2% of the errors caused patient harm. Non-clinical errors (illegibility, missing information, wrong dose) may be affected by a basic electronic prescribing system, and clinical errors (drug–disease interaction, contraindication of a drug) may be affected only when more sophisticated levels of CDS programming are added. Conclusion. Potential prescribing errors occurred frequently but few reached the patient or caused harm. The most severe errors were those that may be reduced by the implementation of an electronic prescribing system with CDS capabilities.
- 23 April 2007
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 23 (6) , 1463-1472
The cost of treating ribavirin-induced anemia in hepatitis C:the impact of using recombinant human erythropoietin
Ribavirin-induced anemia (RIA) is a common adverse effect of chronic hepatitis C treatment. Studies have shown that the use of epoetin decreases the need for ribavirin dose reduction or discontinuation. The primary objective was to calculate the incremental cost of treating hepatitis C in those without versus with RIA, using either the strategy of ribavirin dose reduction/discontinuation or epoetin. The secondary objective was to calculate the incremental cost of using epoetin versus no epoetin to treat RIA, per ribavirin dose reduction/discontinuation averted. Estimates from the literature and decision-analytic techniques were used to model treatment patterns and estimate the cost of managing RIA in genotype 1, 2, and 3 subjects. Sensitivity analyses were used to address uncertainty. Clinically significant RIA, a reduction in hemoglobin of > or = 2 g/dL (1.2 mmol/L), developed in 72% of patients in observational studies. The incremental cost of treating chronic hepatitis C decreased when employing the strategy of ribavirindose reduction/discontinuation to treat RIA, and increased by 5.7% (genotype 1) or 34.4% (genotype 2 or 3), when using epoetin. Using one-way sensitivity analyses, the cost of using epoetin per ribavirin dose reduction/discontinuation averted was $39,579-$52,023. Generalizability may be limited to settings in which a similar proportion of patients develop RIA. The proportional cost of treating hepatitis C when using epoetin to treat RIA is significant in genotype 2 or 3 patients. The cost of using epoetin per ribavirin dose reduction/discontinuation averted is substantial in patients with genotypes 1, 2, or 3; and varies with the probability of response to epoetin. These findings suggest that additional studies are warranted that will determine the effect of epoetin on treatment outcomes and its role as supportive therapy in patients with RIA.
- 23 April 2007
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 23 (6) , 1463-1472
The cost of treating ribavirin-induced anemia in hepatitis C:the impact of using recombinant human erythropoietin
Ribavirin-induced anemia (RIA) is a common adverse effect of chronic hepatitis C treatment. Studies have shown that the use of epoetin decreases the need for ribavirin dose reduction or discontinuation. The primary objective was to calculate the incremental cost of treating hepatitis C in those without versus with RIA, using either the strategy of ribavirin dose reduction/discontinuation or epoetin. The secondary objective was to calculate the incremental cost of using epoetin versus no epoetin to treat RIA, per ribavirin dose reduction/discontinuation averted. Estimates from the literature and decision-analytic techniques were used to model treatment patterns and estimate the cost of managing RIA in genotype 1, 2, and 3 subjects. Sensitivity analyses were used to address uncertainty. Clinically significant RIA, a reduction in hemoglobin of > or = 2 g/dL (1.2 mmol/L), developed in 72% of patients in observational studies. The incremental cost of treating chronic hepatitis C decreased when employing the strategy of ribavirindose reduction/discontinuation to treat RIA, and increased by 5.7% (genotype 1) or 34.4% (genotype 2 or 3), when using epoetin. Using one-way sensitivity analyses, the cost of using epoetin per ribavirin dose reduction/discontinuation averted was $39,579-$52,023. Generalizability may be limited to settings in which a similar proportion of patients develop RIA. The proportional cost of treating hepatitis C when using epoetin to treat RIA is significant in genotype 2 or 3 patients. The cost of using epoetin per ribavirin dose reduction/discontinuation averted is substantial in patients with genotypes 1, 2, or 3; and varies with the probability of response to epoetin. These findings suggest that additional studies are warranted that will determine the effect of epoetin on treatment outcomes and its role as supportive therapy in patients with RIA.